Patient reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analogue liraglutide or glimepiride

被引：0
|
作者：
Bode, B. W. [1 ]
Hale, P. M. [2 ]
Hammer, M. [3 ]
Testa, M. A. [4 ]
Garber, A. [5 ]
机构：
[1] Atlanta Diabet Associates, Atlanta, GA USA
[2] Novo Nordisk Inc, Princeton, NJ USA
[3] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[5] Baylor Coll Med, Houston, TX 77030 USA
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
894
引用
收藏
页码：S357 / S358
页数：2
相关论文
共 50 条
  • [1] Evaluation of patient reported outcomes in subjects with type 2 diabetes treated with the once-daily human GLP-1 analog liraglutide or glimepiride both as add-on to metformin
    Frid, Anders
    Nauck, Michael A.
    Hermansen, Kjeld
    Kolotkin, Ronette L.
    Hammer, Mette
    Zdrav-Kovic, Milan
    Matthews, David
    DIABETES, 2008, 57 : A574 - A575
  • [2] Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus
    Vilsboll, Tina
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (02) : 231 - 237
  • [3] Significantly better glycaemic control and weight reduction with liraglutide, a once-daily human GLP-1 analogue, compared with glimepiride: all as monotherapy in type 2 diabetes
    Garber, A.
    Henry, R.
    Ratner, R.
    Garcia-Hernandez, P.
    Pattzi, H. M. Rodriguez
    Olvera-Alvarez, I.
    Hale, P. M.
    Zdravkovic, M.
    Bode, B.
    DIABETOLOGIA, 2008, 51 : S358 - S359
  • [4] Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes
    Seino, Y.
    Rasmussen, M. F.
    Nishida, T.
    Kaku, K.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (05) : 1013 - 1022
  • [5] Effects of the once-daily human GLP-1 analogue liraglutide on appetite and energy intake in type 2 diabetes
    Horowitz, M.
    Flint, A.
    Doran, S.
    Rasmussen, M. F.
    Kapitza, C.
    Andreasen, A. H.
    Jones, K. L.
    Zdravkovic, M.
    Chapman, I. M.
    DIABETOLOGIA, 2008, 51 : S355 - S355
  • [6] Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide
    Horowitz, M.
    Vilsboll, T.
    Zdravkovic, M.
    Hammer, M.
    Madsbad, S.
    DIABETES OBESITY & METABOLISM, 2008, 10 (07): : 593 - U4
  • [7] Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes
    Ryan, Gina J.
    Hardy, Yolanda
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2011, 36 (03) : 260 - 274
  • [8] The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol
    Kapitza, Christoph
    Flint, Anne
    Hindsberger, Charlotte
    Zdravkovic, Milan
    DIABETES, 2008, 57 : A593 - A593
  • [9] Liraglutide, a once-daily human GLP-1 analog, significantly improves β-cell function in subjects with type 2 diabetes
    Matthews, David
    Marre, Michel
    Le-Thl, T. U. Duyen
    Zdravkovic, Milan
    Simo, Rafael
    DIABETES, 2008, 57 : A150 - A151
  • [10] Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes
    Bode, B. W.
    Testa, M. A.
    Magwire, M.
    Hale, P. M.
    Hammer, M.
    Blonde, L.
    Garber, A.
    DIABETES OBESITY & METABOLISM, 2010, 12 (07): : 604 - 612
12345